Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, Sydney, New South Wales, 2006, Australia.
Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, Sydney, New South Wales, 2006, Australia; Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Centre for Cancer Cell Biology, Griffith Institute for Drug Discovery, Griffith University, Nathan, Brisbane, Queensland, 4111, Australia.
Free Radic Biol Med. 2020 Nov 1;159:177-188. doi: 10.1016/j.freeradbiomed.2020.07.019. Epub 2020 Jul 30.
Redox stress is associated with the pathogenesis of a wide variety of disease states. This can be amplified potentially through redox active iron deposits in oxidatively active organelles such as the mitochondrion. There are a number of disease states, including Friedreich's ataxia (FA) and sideroblastic anemia, where iron metabolism is dysregulated and leads to mitochondrial iron accumulation. Considering FA, which is due to the decreased expression of the mitochondrial protein, frataxin, this iron accumulation does not occur within protective storage proteins such as mitochondrial ferritin. Instead, it forms unbound biomineral aggregates composed of high spin iron(III), phosphorous and sulfur, which probably contributes to the observed redox stress. There is also a dysregulated response to the ensuing redox assault, as the master regulator of oxidative stress, nuclear factor erythroid 2-related factor-2 (Nrf2), demonstrates marked down-regulation. The dysfunctional response of Nrf2 in FA is due to multiple mechanisms including: (1) up-regulation of Keap1 that is involved in Nrf2 degradation; (2) activation of the nuclear Nrf2 export/degradation machinery via glycogen synthase kinase-3β (Gsk3β) signaling; and (3) inhibited nuclear translocation of Nrf2. More recently, increased microRNA (miRNA) 144 expression has been demonstrated to down-regulate Nrf2 in several disease states, including an animal model of FA. Other miRNAs have also demonstrated to be dysregulated upon frataxin depletion in vivo in humans and animal models of FA. Collectively, frataxin depletion results in multiple, complex responses that lead to detrimental redox effects that could contribute to the mechanisms involved in the pathogenesis of FA.
氧化应激与多种疾病状态的发病机制有关。这种情况可能会通过氧化活跃的细胞器(如线粒体)中的氧化还原活性铁沉积而放大。有许多疾病状态,包括弗里德里希共济失调症(FA)和铁幼粒细胞性贫血,其中铁代谢失调导致线粒体铁积累。考虑到 FA 是由于线粒体蛋白 frataxin 的表达减少引起的,这种铁积累不会发生在保护性储存蛋白(如线粒体铁蛋白)中。相反,它形成由高铁(III)、磷和硫组成的未结合生物矿物质聚集体,这可能导致观察到的氧化应激。此外,对随之而来的氧化应激攻击也存在失调反应,因为氧化应激的主要调节剂核因子红细胞 2 相关因子 2(Nrf2)表现出明显的下调。FA 中 Nrf2 的功能障碍反应归因于多种机制,包括:(1)参与 Nrf2 降解的 Keap1 的上调;(2)通过糖原合成酶激酶-3β(Gsk3β)信号激活核 Nrf2 输出/降解机制;和(3)抑制 Nrf2 的核易位。最近,已经证明在几种疾病状态(包括 FA 的动物模型)中,miRNA144 的表达增加会下调 Nrf2。其他 miRNA 也已被证明在人类和 FA 的动物模型中 frataxin 耗竭时失调。总之,frataxin 耗竭导致多种复杂反应,导致有害的氧化还原效应,这可能有助于 FA 发病机制中涉及的机制。